A raised incidence of HL-A2 plus HL-A9 and other anomalies of the HL-A antigens of patients with leukaemia.
In 54 patients with leukaemia a raised incidence of HL-A9 was noted as well as a markedly increased association between this antigen and HL-A2. This occurred most frequently in patients with chronic myeloid leukemia. As HL-A2 and HL-A9 are both antigens of the first series it has been suggested that all the predisposition to develop leukaemia is controlled by a recessive gene closely linked to the first LH-A locus and in a linkage disequilibrium with HL-A2 and HL-A9. 5 patients also showed definite changes between antigens of the same series, whilst other suffered a partial or total loss in antigenicity. Lymphocytes from 145 controls did not behave in this way, though other patients receiving radiotherapy also 'lost' antigens. So it was postulated that such changes resulted from the treatment of the disease rather than the disease itself.
D005787:Gene Frequency; D005808:Genes, Recessive; D008040:Genetic Linkage; D006680:HLA Antigens; D006649:Histocompatibility Antigens; D006650:Histocompatibility Testing; D006801:Humans; D007938:Leukemia / Q000235:genetics / Q000276:immunology*; D007945:Leukemia, Lymphoid / Q000276:immunology; D007951:Leukemia, Myeloid / Q000276:immunology; D015470:Leukemia, Myeloid, Acute / Q000276:immunology
D006680:HLA Antigens; D006649:Histocompatibility Antigens